|

Talimogene Laherparepvec Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Imlygic, T-VEC

Pipeline

Phase 2: 1

Top Sponsors

  • University of Louisville1

Indications

  • Cutaneous Melanoma1
  • Cancer1

Louisville, Kentucky1 trial

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

University of Louisville

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.